Global Radioimmunotherapy Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI05240764

Publication Date:

May 1, 2024

Pages:

134

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Radioimmunotherapy market size is projected to grow from US$ 2332 million in 2024 to US$ 5443 million in 2030; it is expected to grow at a CAGR of 15.2% from 2024 to 2030.
The 鈥淩adioimmunotherapy Industry Forecast鈥� looks at past sales and reviews total world Radioimmunotherapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Radioimmunotherapy sales for 2023 through 2029. With Radioimmunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioimmunotherapy industry.
This Insight Report provides a comprehensive analysis of the global Radioimmunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radioimmunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Radioimmunotherapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioimmunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioimmunotherapy.
Global key Companies of Radioimmunotherapy include Novartis, Bayer, etc. The top two players hold a share over 98%. North America is the largest market, with a share about 62%, followed by Europe and Asia-Pacific, with the share about 29% and 8%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 90%.
This report presents a comprehensive overview, market shares, and growth opportunities of Radioimmunotherapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Beta-emitting
Targeted Alpha Therapy
Segmentation by Application:
Solid Tumor
Non Hodgkin Lymphoma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Beta-emitting
Targeted Alpha Therapy
Segmentation by Application:
Solid Tumor
Non Hodgkin Lymphoma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Radioimmunotherapy Market Size 2019-2030
2.1.2 Radioimmunotherapy Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Radioimmunotherapy by Country/Region, 2019, 2023 & 2030
2.2 Radioimmunotherapy Segment by Type
2.2.1 Beta-emitting
2.2.2 Targeted Alpha Therapy
2.3 Radioimmunotherapy Market Size by Type
2.3.1 Radioimmunotherapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Radioimmunotherapy Market Size Market Share by Type (2019-2024)
2.4 Radioimmunotherapy Segment by Application
2.4.1 Solid Tumor
2.4.2 Non Hodgkin Lymphoma
2.5 Radioimmunotherapy Market Size by Application
2.5.1 Radioimmunotherapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Radioimmunotherapy Market Size Market Share by Application (2019-2024)
3 Radioimmunotherapy Market Size by Player
3.1 Radioimmunotherapy Market Size Market Share by Player
3.1.1 Global Radioimmunotherapy Revenue by Player (2019-2024)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Player (2019-2024)
3.2 Global Radioimmunotherapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Radioimmunotherapy by Region
4.1 Radioimmunotherapy Market Size by Region (2019-2024)
4.2 Global Radioimmunotherapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Radioimmunotherapy Market Size Growth (2019-2024)
4.4 APAC Radioimmunotherapy Market Size Growth (2019-2024)
4.5 Europe Radioimmunotherapy Market Size Growth (2019-2024)
4.6 Middle East & Africa Radioimmunotherapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Radioimmunotherapy Market Size by Country (2019-2024)
5.2 Americas Radioimmunotherapy Market Size by Type (2019-2024)
5.3 Americas Radioimmunotherapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radioimmunotherapy Market Size by Region (2019-2024)
6.2 APAC Radioimmunotherapy Market Size by Type (2019-2024)
6.3 APAC Radioimmunotherapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Radioimmunotherapy Market Size by Country (2019-2024)
7.2 Europe Radioimmunotherapy Market Size by Type (2019-2024)
7.3 Europe Radioimmunotherapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Radioimmunotherapy by Region (2019-2024)
8.2 Middle East & Africa Radioimmunotherapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Radioimmunotherapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Radioimmunotherapy Market Forecast
10.1 Global Radioimmunotherapy Forecast by Region (2025-2030)
10.1.1 Global Radioimmunotherapy Forecast by Region (2025-2030)
10.1.2 Americas Radioimmunotherapy Forecast
10.1.3 APAC Radioimmunotherapy Forecast
10.1.4 Europe Radioimmunotherapy Forecast
10.1.5 Middle East & Africa Radioimmunotherapy Forecast
10.2 Americas Radioimmunotherapy Forecast by Country (2025-2030)
10.2.1 United States Market Radioimmunotherapy Forecast
10.2.2 Canada Market Radioimmunotherapy Forecast
10.2.3 Mexico Market Radioimmunotherapy Forecast
10.2.4 Brazil Market Radioimmunotherapy Forecast
10.3 APAC Radioimmunotherapy Forecast by Region (2025-2030)
10.3.1 China Radioimmunotherapy Market Forecast
10.3.2 Japan Market Radioimmunotherapy Forecast
10.3.3 Korea Market Radioimmunotherapy Forecast
10.3.4 Southeast Asia Market Radioimmunotherapy Forecast
10.3.5 India Market Radioimmunotherapy Forecast
10.3.6 Australia Market Radioimmunotherapy Forecast
10.4 Europe Radioimmunotherapy Forecast by Country (2025-2030)
10.4.1 Germany Market Radioimmunotherapy Forecast
10.4.2 France Market Radioimmunotherapy Forecast
10.4.3 UK Market Radioimmunotherapy Forecast
10.4.4 Italy Market Radioimmunotherapy Forecast
10.4.5 Russia Market Radioimmunotherapy Forecast
10.5 Middle East & Africa Radioimmunotherapy Forecast by Region (2025-2030)
10.5.1 Egypt Market Radioimmunotherapy Forecast
10.5.2 South Africa Market Radioimmunotherapy Forecast
10.5.3 Israel Market Radioimmunotherapy Forecast
10.5.4 Turkey Market Radioimmunotherapy Forecast
10.6 Global Radioimmunotherapy Forecast by Type (2025-2030)
10.7 Global Radioimmunotherapy Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Radioimmunotherapy Forecast
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Radioimmunotherapy Product Offered
11.1.3 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Radioimmunotherapy Product Offered
11.2.3 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Lantheus
11.3.1 Lantheus Company Information
11.3.2 Lantheus Radioimmunotherapy Product Offered
11.3.3 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Lantheus Main Business Overview
11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Information
11.4.2 Aurobindo Pharma Radioimmunotherapy Product Offered
11.4.3 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Aurobindo Pharma Main Business Overview
11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Radioimmunotherapy Product Offered
11.5.3 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Information
11.6.2 China Isotope & Radiation Radioimmunotherapy Product Offered
11.6.3 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 China Isotope & Radiation Main Business Overview
11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Information
11.7.2 Curium Pharmaceuticals Radioimmunotherapy Product Offered
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Curium Pharmaceuticals Main Business Overview
11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Radioimmunotherapy Product Offered
11.8.3 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Information
11.9.2 Clarity Pharmaceuticals Radioimmunotherapy Product Offered
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Clarity Pharmaceuticals Main Business Overview
11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
11.10.1 Curasight Company Information
11.10.2 Curasight Radioimmunotherapy Product Offered
11.10.3 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Curasight Main Business Overview
11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Information
11.11.2 Nordic Nanovector Radioimmunotherapy Product Offered
11.11.3 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Nordic Nanovector Main Business Overview
11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
11.12.1 Philogen Company Information
11.12.2 Philogen Radioimmunotherapy Product Offered
11.12.3 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Philogen Main Business Overview
11.12.5 Philogen Latest Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Information
11.13.2 RadioMedix Radioimmunotherapy Product Offered
11.13.3 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 RadioMedix Main Business Overview
11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Information
11.14.2 Telix Pharmaceuticals Radioimmunotherapy Product Offered
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Telix Pharmaceuticals Main Business Overview
11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
11.15.1 Orano Med Company Information
11.15.2 Orano Med Radioimmunotherapy Product Offered
11.15.3 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Orano Med Main Business Overview
11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Information
11.16.2 Actinium Pharmaceuticals Radioimmunotherapy Product Offered
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Actinium Pharmaceuticals Main Business Overview
11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Information
11.17.2 Y-mAbs Therapeutics Radioimmunotherapy Product Offered
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Y-mAbs Therapeutics Main Business Overview
11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Information
11.18.2 Fusion Pharmaceuticals Radioimmunotherapy Product Offered
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Fusion Pharmaceuticals Main Business Overview
11.18.5 Fusion Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂